Table 4.
Flow cytometry analysis of PBMCs from patients 1 (A) and 14 (B) uninfected or 24 hours after infection with 5 MOI of MVA-WT or 5 MOI of MVA-TRICOM
| Vector | B7-1, % (MFI) | ICAM-1, % (MFI) | LFA-3, % (MFI) |
|---|---|---|---|
| Patient 1 | |||
| Uninfected | 4.9 (23) | 22.2 (18) | 83.4 (25) |
| MVA-WT | 3.1 (16) | 13.6 (16) | 83.5 (25) |
| MVA-TRICOM (combined) | 68.9 (672) | 82.0 (2131) | 92.6 (987) |
| MVA-TRICOM (low MFI) | 36.5 (20) | 62.0 (32) | 88.6 (33) |
| MVA-TRICOM (high MFI) | 95.9 (920) | 96.2 (3226) | 96.1 (1949) |
| Patient 14 | |||
| Uninfected | 0.7 (2) | 26.9 (63) | 69.9 (36) |
| MVA-WT | 0.2 (2) | 18.7 (50) | 73.7 (27) |
| MVA-TRICOM (combined) | 81.8 (979) | 93.1 (2476) | 95.0 (1095) |
| MVA-TRICOM (low MFI) | 40.3 (43) | 70.5 (50) | 88.4 (45) |
| MVA-TRICOM (high MFI) | 98.8 (1534) | 99.6 (3133) | 99.2 (1766) |
The percentage of double-positive cells (for CD19 and each costimulatory molecule), as well as MFI value for the expression of each costimulatory molecule (numbers in parentheses), are shown. Data on the combined populations were calculated as the percentage of double-positive cells in the entire PBMC population; data on the low MFI and high MFI populations were calculated after gating on each individual population of CLL cells.